UTAA09 cell therapy for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called UTAA09 for people with certain types of lymphoma that have not been treated with CAR T-cells before. It aims to see if the treatment is safe and works against tumors that have CD19 or CD20 proteins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma that is large B-cell, follicular, mantle cell, or has transformed to diffuse large B-cell lymphoma.
- Your lymphoma cells show a protein called CD19 and/or CD20.
- You have at least one tumor that can be measured on a scan (like a lymph node bigger than 1.5 cm or a tumor outside the lymph node bigger than 1 cm).
- You are in fairly good health (able to do daily activities without much trouble).
- You have not received CAR T-cell therapy or other gene-modified cell therapy before.
- You are not on long-term steroids (except inhalers or creams) and do not have unstable heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy called UTAA09 for people with CD19-positive B-cell blood cancers that have come back or not responded to treatment. It aims to see if this treatment is safe and effective.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
Hear when a new Recurrent or Refractory B-cell Non Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.